New treatment identified for low grade and serous ovarian cancer

May 2022: Trametinib may become a new standard of care for recurring, low-grade serous ovarian cancer (Mekinist). According to study findings published in the February 2022 issue of The Lancet, trametinib beat both chemotherapy and anti-estrogens like tamoxifen by around 52 percent, adding six months of progression-free (period during which the cancer did not advance) survival for patients.

In 260 women with recurrent serous ovarian tumours who had previously received chemotherapy, researchers from the United States and the United Kingdom compared once-daily oral trametinib to one of five standard of care regimens (either chemotherapy or anti-estrogen medications). When compared to usual treatment, trametinib participants showed a fourfold higher response to therapy after 15 months. Trametinib outperformed all other treatments, slowing disease progression for 13 months (versus seven months for standard treatment). Skin rash, anaemia, high blood pressure, diarrhoea, and weariness are some of the potentially dangerous adverse effects of trametinib treatment.

Low-grade serous ovarian cancer is a difficult-to-treat invasive form of ovarian cancer marked by strong hormone receptor activation, genetic alterations, and poor chemotherapy response. Until now, the cancer toolbox lacked effective therapeutic options for patients with low-grade serous ovarian cancer. According to an editorial accompanying the report, 70% of these women will recur, with only 5% responding to further chemotherapy.

Susan Hau

Website |  + postsBio ⮌

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

• Susan Hau

  https://cancerfax.com/author/susan/

  Gene Therapy for Gaucher’s Disease in China
• Susan Hau

  https://cancerfax.com/author/susan/

  Gene Therapy for Wilson’s Disease in China
• Susan Hau

  https://cancerfax.com/author/susan/

  Gene Therapy for Phenylketonuria in China
• Susan Hau

  https://cancerfax.com/author/susan/

  Best Cancer Hospitals in China 2025